Backus Hospital to host annual safety camp
The free event will be held in the hospital parking lot at 326 Washington Street in Norwich.
Jennifer Monahan, a nurse in the hospital's emergency department and one of the lead organizers of the safety camp event, joined Good Morning Connecticut at 9 a.m. to discuss.
Watch the video above.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Merck & Co. (MRK) Announces that US FDA Approves ENFLONSIA™ For Preventing RSV Lower Respiratory Tract Disease
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who were born during or entering their first RSV season. To provide a brief context, ENFLONSIA happens to be a preventive, long-acting monoclonal antibody (mAb) which has been designed to offer direct, rapid, and durable protection through 5 months, a typical RSV season, with the same 105 mg dose irrespective of weight. Merck & Co., Inc. (NYSE:MRK) further mentioned that the typical RSV season generally spans autumn to spring of the next year. A close-up of a person's hand holding a bottle of pharmaceuticals. However, ENFLONSIA should not be administered to infants who have a history of serious hypersensitivity reactions, including anaphylaxis, to any of the components of ENFLONSIA. Merck & Co., Inc. (NYSE:MRK) added that the approval is basis the results from the pivotal Phase 2b/3 CLEVER trial (MK-1654-004) evaluating a single dose of ENFLONSIA administered to preterm and full-term infants. Furthermore, the focus is to ensure the availability of ENFLONSIA in the US before the upcoming RSV season begins. This is to help in reducing the significant burden of the widespread seasonal infection on families and health care systems. Artisan Partners, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Shares of Merck & Co., Inc. (NYSE:MRK), a health care solutions company, were down 9%. Operating results have been solid, with Q4 earnings beating expectations, but investors were more focused on the continued weak demand in China for Gardasil, a vaccine for human papillomavirus (HPV), and the company's decision to pause vaccine shipments through at least mid-2025 to pare inventories. Though recent Gardasil setbacks have weighed on sentiment, the overarching issue for shareholders remains the success of Merck's late-stage pipeline to replace sales that will be lost when blockbuster oncology drug Keytruda (50% of Q4sales) comes off patent in 2028. As shares sell cheaply at just 10X earnings, Merck seems to be getting little credit from investors for the 60+ programs it has in clinical development, despite having several solid and large new product opportunities. Additionally, the company's strong balance sheet and robust free cash flow provide it multiple options for future partnerships and acquisitions, besides return of capital to shareholders via dividends and share repurchases.' While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data
Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc. (NASDAQ:EDIT) revealed new in vivo data showing notable progress in gene editing for beta thalassemia and sickle cell disease. According to the study, a single dose of the company's proprietary targeted lipid nanoparticle (tLNP) in non-human primates exceeded the therapeutic threshold by achieving a mean on-target editing level of 58% in the HBG1/2 promoter region of hematopoietic stem cells. Editas' position in the gene editing market is strengthened by the result, enhancing the company's potential to offer a novel treatment for these illnesses with favorable biodistribution and minimal liver targeting. A clinical-stage biotechnology company, Editas Medicine, Inc. (NASDAQ:EDIT) develops gene-editing treatments that use CRISPR technology to modify patients' genomes to treat genetic diseases. Editas distinguishes itself from other major biotech companies that are seeking alternative genomic therapeutics by using an 'in vivo gene editing upregulation strategy.' While we acknowledge the potential of EDIT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
4 hours ago
- Yahoo
Sana Reports Promising Diabetes Cell Therapy Data at ADA Meeting
Sana Biotechnology, Inc. (NASDAQ:SANA) ranks among the best CRISPR stocks to buy. On June 24, Citizens JMP reaffirmed its $5 price target and Market Outperform rating for Sana Biotechnology, Inc. (NASDAQ:SANA) in light of new clinical data from its diabetes therapy program. Pixabay/Public Domain The biotechnology company attended the American Diabetes Association meeting and presented new results from its UP421 cadaveric pancreatic islet cell program. The findings showed that people with Type 1 diabetes can still safely and well tolerate islet cells. At the 24-week milestone, the findings indicated that the transplanted cells were still alive and generating insulin without the need for immunosuppression, according to Citizens JMP. This was verified by MRI imaging, mixed-meal tolerance testing, and baseline C-peptide levels. Sana Biotechnology, Inc. (NASDAQ:SANA) is a Seattle, Washington-based company that specializes in developing treatments for complex diseases like diabetes, cancer, and nervous system disorders. The company's potential for success is largely influenced by its R&D pipeline. Back in 2021, the company inked a deal with Beam Therapeutics for the non-exclusive commercial rights to the biotech's CRISPR-Cas12b gene editing system. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
